Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

2.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.9K
The Two-State Receptor Model01:29

The Two-State Receptor Model

1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
1.9K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

5.1K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.1K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

973
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
973

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

G protein-biased signaling activates PKCβII by outcompeting arrestin3 for Mdm2-mediated ubiquitination.

Life sciences·2026
Same author

Thiazole-Linked <i>N</i>-Hydroxypropanamide Derivatives: Selective HDAC6 Inhibitors with Therapeutic Potential for Neurodegenerative Diseases.

Journal of medicinal chemistry·2026
Same author

Structure-Activity Relationships and Ligand-Dependent Arrestin Bias in μ-Opioid Receptor-Mediated ERK Activation.

Biomolecules & therapeutics·2026
Same author

Spatiotemporal dynamics of β-arrestin-mediated Src activation in 5-HT7 receptor signaling pathway.

The FEBS journal·2026
Same author

α<sub>2C</sub> Adrenoceptor antagonist KMCA-0011 alleviated depressive-like behaviors in a maternal separation mouse model.

Bioorganic & medicinal chemistry letters·2025
Same author

Integrating allostasis and emerging technologies to study complex diseases.

Communications biology·2025

Related Experiment Video

Updated: Jun 24, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K

Structure-Activity Relationship and Functional Evaluation of Cannabinoid Type-1 Receptor.

Shujie Wang1, Xinru Tian1, Suresh Paudel1

  • 1Pharmacology Laboratory, College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea.

Biomolecules & Therapeutics
|June 6, 2024
PubMed
Summary

Researchers identified key structural features of cannabinoid receptor 1 (CB1R) ligands to improve drug design. This study enhances understanding of CB1R ligands for potential treatments of neuropsychological and neurodegenerative disorders.

Keywords:
Cannabinoid type 1 receptorERKG proteinLigand affinityStructure-activity relationship

More Related Videos

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.2K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

463

Related Experiment Videos

Last Updated: Jun 24, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.2K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

463

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Neuroscience

Background:

  • The type-1 cannabinoid receptor (CB1R) is a crucial target for treating neuropsychological and neurodegenerative diseases.
  • Deriving general structure-activity relationships (SARs) for CB1R ligands is challenging due to their structural diversity.

Purpose of the Study:

  • To classify CB1R ligands into structural families and determine their SARs for CB1R affinity.
  • To evaluate the functional activities of these ligands, specifically their role in activating extracellular signal-regulated kinases (ERKs).

Main Methods:

  • Classification of CB1R ligands into six distinct structural families.
  • Determination of SARs for ligand affinity to CB1R.
  • Assessment of functional activities via ERK activation assays.

Main Results:

  • For indol-3-yl-methanone derivatives, optimal affinity was achieved with pentyl and naphthalenyl groups at specific positions.
  • Fluorine substitution on the pentyl group and N1 substituents significantly enhanced affinity in adamantane indazole-3-carboxamide derivatives.
  • 4-alkoxynaphthalene moieties in (naphthalen-1-yl) methanone derivatives improved CB1R affinity compared to heterocyclic rings.
  • A correlation between functional activity (ERK assay) and CB1R affinity suggests agonistic properties for the tested compounds.

Conclusions:

  • The study provides valuable insights for designing novel CB1R ligands.
  • These findings can aid in developing treatments for psychiatric disorders and drug abuse.